Teva Pharmaceutical Industries Other Operating Income or Expenses 2010-2024 | TEVA
Teva Pharmaceutical Industries annual/quarterly other operating income or expenses history and growth rate from 2010 to 2024. Other operating income or expenses can be defined as the aggregate amount of all operating expenses either too small to report separately or that cannot be standardized into another Zacks field.
- Teva Pharmaceutical Industries other operating income or expenses for the quarter ending June 30, 2024 were $-0.081B, a 81.12% decline year-over-year.
- Teva Pharmaceutical Industries other operating income or expenses for the twelve months ending June 30, 2024 were $-0.522B, a 39.86% decline year-over-year.
- Teva Pharmaceutical Industries annual other operating income or expenses for 2023 were $-0.994B, a 49.67% decline from 2022.
- Teva Pharmaceutical Industries annual other operating income or expenses for 2022 were $-1.975B, a 219.06% increase from 2021.
- Teva Pharmaceutical Industries annual other operating income or expenses for 2021 were $-0.619B, a 2995% increase from 2020.
Teva Pharmaceutical Industries Annual Other Operating Income or Expenses
(Millions of US $) |
| 2023 |
$-994 |
| 2022 |
$-1,975 |
| 2021 |
$-619 |
| 2020 |
$-20 |
| 2019 |
$-1,102 |
| 2018 |
$1,499 |
| 2017 |
$699 |
| 2016 |
$-130 |
| 2015 |
$-465 |
| 2014 |
$111 |
| 2013 |
$-1,524 |
| 2012 |
$-715 |
| 2011 |
$-471 |
| 2010 |
$-410 |
| 2009 |
$-638 |
Teva Pharmaceutical Industries Quarterly Other Operating Income or Expenses
(Millions of US $) |
| 2024-06-30 |
$-81 |
| 2024-03-31 |
$-107 |
| 2023-12-31 |
$-29 |
| 2023-09-30 |
$-305 |
| 2023-06-30 |
$-429 |
| 2023-03-31 |
$-231 |
| 2022-12-31 |
$-15 |
| 2022-09-30 |
$-193 |
| 2022-06-30 |
$-695 |
| 2022-03-31 |
$-1,072 |
| 2021-12-31 |
$-579 |
| 2021-09-30 |
$22 |
| 2021-06-30 |
$37 |
| 2021-03-31 |
$-99 |
| 2020-12-31 |
$-41 |
| 2020-09-30 |
$-13 |
| 2020-06-30 |
$-4 |
| 2020-03-31 |
$38 |
| 2019-12-31 |
$40 |
| 2019-09-30 |
$-454 |
| 2019-06-30 |
$-637 |
| 2019-03-31 |
$-51 |
| 2018-12-31 |
$-74 |
| 2018-09-30 |
$16 |
| 2018-06-30 |
$76 |
| 2018-03-31 |
$1,481 |
| 2017-12-31 |
$923 |
| 2017-09-30 |
$24 |
| 2017-06-30 |
$-300 |
| 2017-03-31 |
$52 |
| 2016-12-31 |
$544 |
| 2016-09-30 |
$-533 |
| 2016-06-30 |
$-166 |
| 2016-03-31 |
$25 |
| 2015-12-31 |
$66 |
| 2015-09-30 |
$80 |
| 2015-06-30 |
$-384 |
| 2015-03-31 |
$-227 |
| 2014-12-31 |
$44 |
| 2014-09-30 |
$122 |
| 2014-06-30 |
$-26 |
| 2014-03-31 |
$-29 |
| 2013-12-31 |
$-15 |
| 2013-09-30 |
$-47 |
| 2013-06-30 |
$-1,435 |
| 2013-03-31 |
$-27 |
| 2012-12-31 |
$620 |
| 2012-09-30 |
$-1,131 |
| 2012-06-30 |
$-55 |
| 2012-03-31 |
$-149 |
| 2011-12-31 |
$-119 |
| 2011-09-30 |
$-51 |
| 2011-06-30 |
$-272 |
| 2011-03-31 |
$-29 |
| 2010-12-31 |
$-332 |
| 2010-09-30 |
$-53 |
| 2010-06-30 |
$9 |
| 2010-03-31 |
$-34 |
| 2009-12-31 |
|
| 2009-09-30 |
|
| 2009-06-30 |
|
| 2009-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$20.120B |
$15.846B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
